Search Results - "SHENK KEVIN" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

by ARASTU-KAPUR, Shirin, ANDERL, Janet L, KIRK, Christopher J, KRAUS, Marianne, PARLATI, Francesco, SHENK, Kevin D, LEE, Susan J, MUCHAMUEL, Tony, BENNETT, Mark K, DRIESSEN, Christoph, BALL, Andrew J
Published in Clinical cancer research (01.05.2011)

Get full text

Journal Article

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

by Parlati, Francesco, Lee, Susan J., Aujay, Monette, Suzuki, Erika, Levitsky, Konstantin, Lorens, James B., Micklem, David R., Ruurs, Paulina, Sylvain, Catherine, Lu, Yan, Shenk, Kevin D., Bennett, Mark K.
Published in Blood (15.10.2009)

Get full text

Journal Article

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

by Kuhn, Deborah J., Chen, Qing, Voorhees, Peter M., Strader, John S., Shenk, Kevin D., Sun, Congcong M., Demo, Susan D., Bennett, Mark K., van Leeuwen, Fijs W.B., Chanan-Khan, Asher A., Orlowski, Robert Z.
Published in Blood (01.11.2007)

Get full text

Journal Article

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

by DEMO, Susan D, KIRK, Christopher J, SHENK, Kevin D, SMYTH, Mark S, SUN, Congcong M, VALLONE, Marcy K, WOO, Tina M, MOLINEAUX, Christopher J, BENNETT, Mark K, AUJAY, Monette A, BUCHHOLZ, Tonia J, DAJEE, Maya, HO, Mark N, JING JIANG, LAIDIG, Guy J, LEWIS, Evan R, PARLATI, Francesco
Published in Cancer research (Chicago, Ill.) (01.07.2007)

Get full text

Journal Article

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)

by Zhou, Han-Jie, Aujay, Monette A, Bennett, Mark K, Dajee, Maya, Demo, Susan D, Fang, Ying, Ho, Mark N, Jiang, Jing, Kirk, Christopher J, Laidig, Guy J, Lewis, Evan R, Lu, Yan, Muchamuel, Tony, Parlati, Francesco, Ring, Eileen, Shenk, Kevin D, Shields, Jamie, Shwonek, Peter J, Stanton, Timothy, Sun, Congcong M, Sylvain, Catherine, Woo, Tina M, Yang, Jinfu
Published in Journal of medicinal chemistry (14.05.2009)

Get full text

Journal Article

CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability

CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability

by Elzein, Elfatih, Ibrahim, Prabha, Koltun, Dmitry O., Rehder, Ken, Shenk, Kevin D., Marquart, Timothy A., Jiang, Bob, Li, Xiaofen, Natero, Reina, Li, Yuan, Nguyen, Marie, Kerwar, Suresh, Chu, Nancy, Soohoo, Daniel, Hao, Jia, Maydanik, Victoria Y., Lustig, David A., Zeng, Dewan, Leung, Kwan, Zablocki, Jeff A.
Published in Bioorganic & medicinal chemistry letters (20.12.2004)

Get full text

Journal Article

Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents

by MORRISON, Christopher F, ELZEIN, Elfatih, YUZHI WU, DEWAN ZENG, IRVING FONG, LUSTIG, David, KWAN LEUNG, ZABLOCKI, Jeff A, JIANG, Bob, IBRAHIM, Prabha N, MARQUART, Timothy, PALLE, Venkata, SHENK, Kevin D, VARKHEDKAR, Vaibhav, TENNING MAA, LIN WU
Published in Bioorganic & medicinal chemistry letters (16.07.2004)

Get full text

Journal Article

New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties

New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties

by Koltun, Dmitry O., Marquart, Timothy A., Shenk, Kevin D., Elzein, Elfatih, Li, Yuan, Nguyen, Marie, Kerwar, Suresh, Zeng, Dewan, Chu, Nancy, Soohoo, Daniel, Hao, Jia, Maydanik, Victoria Y., Lustig, David A., Ng, Khing-Jow, Fraser, Heather, Zablocki, Jeffery A.
Published in Bioorganic & medicinal chemistry letters (19.01.2004)

Get full text

Journal Article

Non-Proteasomal Targets of Proteasome Inhibitors Bortezomib and Carfilzomib

Non-Proteasomal Targets of Proteasome Inhibitors Bortezomib and Carfilzomib

by Arastu-Kapur, Shirin, Shenk, Kevin, Parlati, Francesco, Bennett, Mark K
Published in Blood (16.11.2008)

Get full text

Journal Article

COMPOUNDS FOR IMMUNOPROTEASOME INHIBITION

COMPOUNDS FOR IMMUNOPROTEASOME INHIBITION

by SHENK KEVIN D, BENNETT MARK K, PARLATI FRANCESCO
Year of Publication 05.07.2013

Get full text

Patent

COMPOUNDS FOR ENZYME INHIBITION

COMPOUNDS FOR ENZYME INHIBITION

by SUN CONGCONG M, ZHOU HAN JIE, SHENK KEVIN D, LAIDIG GUY J
Year of Publication 24.04.2013

Get full text

Patent

Synthesis of conformationally restricted substance P antagonists

Synthesis of conformationally restricted substance P antagonists

by Howard, Harry R., Shenk, Kevin D., Coffman, Karen C., Bryce, Dianne K., Crawford, Rosemary T., McLean, Stafford A.
Published in Bioorganic & medicinal chemistry letters (01.01.1995)

Get full text

Journal Article

COMPOUNDS FOR ENZYME INHIBITION

COMPOUNDS FOR ENZYME INHIBITION

by SUN CONGCONG M, ZHOU HAN JIE, SHENK KEVIN D, LAIDIG GUY J
Year of Publication 23.10.2012

Get full text

Patent

Anti-Tumor Activity of Immunoproteasome Selective Inhibitors

Anti-Tumor Activity of Immunoproteasome Selective Inhibitors

by Parlati, Francesco, Aujay, Monette, Bedringaas, Siv Lise, Demo, Susan, Gjertsen, Bjorn, Goldstein, Eileen, Jiang, Jing, Kirk, Christopher, Laidig, Guy, Lorens, James, Lu, Yan, Micklem, David, Ruurs, Paulina, Shenk, Kevin, Sylvain, Catherine, Sun, Congcong, Woo, Tina, Zhou, Han-Jie, Bennett, Mark
Published in Blood (16.11.2007)

Get full text

Journal Article

The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells

The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells

by Ivancsits, Douglas, Nimmanapali, Rama, Sun, Megan, Shenk, Kevin, Demo, Susan D., Bennett, Mark K., Dalton, William S., Alsina, Melissa
Published in Blood (16.11.2005)

Get full text

Journal Article

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity

by Demo, Susan D., Aujay, Monette A., Goldstein, Eileen, Laidig, Guy J., Parlati, Francesco, Lu, Yan, Shenk, Kevin D., Sun, Congcong M., Sylvain, Catherine, Woo, Tina M., Zhou, Hanjie, Bennett, Mark K.
Published in Blood (16.11.2006)

Get full text

Journal Article

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders

by Parlati, Francesco, Aujay, Monette A., Demo, Susan D., Goldstein, Eileen D., Jiang, Jing, Kirk, Christopher J., Laidig, Guy J., Lu, Yan, Muchamuel, Tony, Shenk, Kevin D., Sylvain, Catherine, Sun, Congcong M., Woo, Tina M., Zhou, Han-Jie, Bennett, Mark K.
Published in Blood (16.11.2006)

Get full text

Journal Article

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance

by Kuhn, Deborah J., Chen, Qing, Voorhees, Peter M., Strader, John S., Shenk, Kevin D., Sun, Congcong M., Demo, Susan D., Bennett, Mark K., van Leeuwen, Fred W., Orlowski, Robert Z.
Published in Blood (16.11.2006)

Get full text

Journal Article

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma

by Kuhn, Deborah J., Voorhees, Peter M., Strader, John S., Shenk, Kevin D., Sun, Congcong M., Demo, Susan D., Bennett, Mark K., Orlowski, Robert Z.
Published in Blood (16.11.2005)

Get full text

Journal Article

PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS

PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS

by ZABLOCKI JEFF, PERRY THAO, XIAO DENGMING, ELZEIN ELFATIH, SHENK KEVIN, LI XIAOFEN, IBRAHIM PRABHA, JIANG ROBERT, MORRISON CHRISTOPHER
Year of Publication 04.05.2010

Get full text

Patent

1
2
3
4
5
6
7
8
9
10
11
Next
[19]